Secondarily, studies have shown that expression of PD-L1 confers a proliferation advantage for MM cells by activating the phosphoinositide 3-kinases (PI3K) signaling pathway, which induces resistance to antimyeloma chemotherapy, including melphalan and bortezomib [15]. Here, CD274 is linked to Miyoshi myopathy.